Introduction {#sec1-1}
============

Different epidemiological study designs are available, one of which is the randomized control trial (RCT). RCTs are the gold standard in evaluating and efficiently translating research data into clinical practice. In fact, this type of study provides the fundamentals of evidence-based medicine and is the most reliable research design out of all of the epidemiological studies available.\[[@ref1]\] Therefore reporting of these invaluable interventions require high-quality reporting techniques, which allow transparency while enabling the readers to critically appraise the trial findings. In order to avoid systematic reporting errors while ascertaining the high-quality reporting standards of RCTs, the CONSORT statement was coined in 1996.\[[@ref2]\] The CONSORT was revised over the years to provide clearer explanations and elaborations of the CONSORT principles. The last version was established in 2010 (available at [www.consort-statement.org](http://www.consort-statement.org)), on which this article will be based.\[[@ref2]\] In fact, the original articles publishing the CONSORT 2010 statement together with their bibliographies were identified and thoroughly reviewed.

The CONSORT Statement {#sec1-2}
=====================

The CONSORT stands for "Consolidated Standards of Reporting Trails" and was developed to aid authors to present the RCTs in a clean, transparent and complete manner, and not to act as a quality assessment tool. The CONSORT is composed of a 25-item checklist, which focuses on the reporting of the trial design, analysis, and interpretation, as seen in [Table 1](#T1){ref-type="table"}.\[[@ref2][@ref3][@ref4]\] A CONSORT flowchart is also available, which displays the progress of all participants through the trail, as seen in [Figure 1](#F1){ref-type="fig"}.\[[@ref4]\]

###### 

The CONSORT 2010 checklist

  CONSORT 2010 checklist                                                                                                          
  ------------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title and abstract                                      1a                                                                      Identification as a randomized trial in the title
  1b                                                      Structured summary of trial design, methods, results, and conclusions   
  Introduction                                                                                                                    
   Background and objectives                              2a                                                                      Scientific background and explanation of the rationale
                                                          2b                                                                      Specific objectives or hypotheses
  Methods                                                                                                                         
   Trial design                                           3a                                                                      Description of trial design (such as parallel, factorial) including allocation ratio
                                                          3b                                                                      Important changes to methods after trial commencement (such as eligibility criteria), with reasons
   Participants                                           4a                                                                      Eligibility criteria for participants
                                                          4b                                                                      Settings and locations where the data were collected
   Interventions                                          5                                                                       The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
   Outcomes                                               6a                                                                      Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
                                                          6b                                                                      Any changes to trial outcomes after the trial commenced, with reasons
   Sample size                                            7a                                                                      How sample size was determined?
                                                          7b                                                                      When applicable, explanation of any interim analyses and stopping guidelines
  Randomization                                                                                                                   
   Sequence generation                                    8a                                                                      The method used to generate the random allocation sequence
                                                          8b                                                                      Type of randomization; details of any restriction (such as blocking and block size)
   Allocation concealment mechanism                       9                                                                       The mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
   Implementation                                         10                                                                      Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
   Blinding                                               11a                                                                     If done, who was blinded after assignment to interventions (e.g., participants, care providers, those assessing outcomes) and how
                                                          11b                                                                     If relevant, description of the similarity of interventions
   Statistical methods                                    12a                                                                     Statistical methods used to compare groups for primary and secondary outcomes
                                                          12b                                                                     Methods for additional analyses, such as subgroup analyses and adjusted analyses
  Results                                                                                                                         
   Participant flow (a diagram is strongly recommended)   13a                                                                     For each group, the numbers of participants who were randomly assigned received intended treatment and were analyzed for the primary outcome
                                                          13b                                                                     For each group, losses and exclusions after randomization, together with reasons
   Recruitment                                            14a                                                                     Dates defining the periods of recruitment and follow-up
                                                          14b                                                                     Why the trial ended or was stopped
   Baseline data                                          15                                                                      A table showing the baseline demographic and clinical characteristics for each group
   Numbers analyzed                                       16                                                                      For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
   Outcomes and estimation                                17a                                                                     For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
                                                          17b                                                                     For binary outcomes, presentation of both absolute and relative effect sizes is recommended
   Ancillary analyses                                     18                                                                      Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
   Harms                                                  19                                                                      All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
  Discussion                                                                                                                      
   Limitations                                            20                                                                      Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, the multiplicity of analyses
   Generalizability                                       21                                                                      Generalizability (external validity, applicability) of the trial findings
   Interpretation                                         22                                                                      Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
  Other information                                                                                                               
   Registration                                           23                                                                      Registration number and name of trial registry
   Protocol                                               24                                                                      Where the full trial protocol can be accessed, if available
   Funding                                                25                                                                      Sources of funding and other support (such as the supply of drugs), the role of funders

![The CONSORT 2010 flowchart](SJA-13-27-g001){#F1}

The CONSORT Checklist {#sec1-3}
=====================

A brief description of each checklist item is provided below.\[[@ref2][@ref3]\]

Item 1: Title and abstract {#sec2-1}
--------------------------

The manuscript title should include the words "randomized trial" in order to ensure correct indexing of the manuscript in electronic databases. Indexing of the published manuscript is of utmost importance to ensure identification of the manuscript as describing a trial. Furthermore, correct indexing also enhances the visibility of a researcher\'s work and increases the citation potential of the published manuscript. Citation of published manuscripts is imperative for the enhancement of the researcher\'s research metrics and for increasing the prestigious acknowledgment of the researcher and his/her work within the scientific community.\[[@ref5]\]

The abstract should include a structured, brief, and clear summary of the study while presenting information found within the actual body of the manuscript. The abstract needs to be well written, since readers tend to assess the overall quality of the trial just by reading the abstract. Furthermore, since not all trial reports are fully freely available for readers, the abstract may be the only source of initial information accessible to readers.\[[@ref3]\]

Item 2: Introduction {#sec2-2}
--------------------

The Introduction section sets the scientific scene and rational as to why the trial was essential. Trials involving human subjects should have an ethical clearance and exhibit substantial benefit toward mankind.

The objective and hypothesis set out to be investigated in the trial should be reported clearly in this section.

Item 3 to 12: Methods {#sec2-3}
---------------------

The Methods section should include a detailed report of how the trial was conducted including the type of design followed and the description of the protocol followed. The type of trial conducted needs to be noted clearly i.e., whether it consisted of a parallel group design or a factorial design.\[[@ref3]\] The most common trial design followed is a randomized parallel group design, and in fact the CONSORT statement focuses mainly on such a trial design.\[[@ref6]\] It is essential that all the eligibility criteria utilized in the trial protocol are clearly defined since this will enable the reader to interpret the study results adequately. Furthermore, the setting and location (county, city, hospital, and clinic) of the trial needs to be reported, since such information impacts on the study\'s validity.\[[@ref3]\]

Sufficient detail on the intervention and the control groups are required to enable the reproducibility of the trial. When a drug intervention trial is being reported, it is essential that the drug name, dose, mode of administration, timing, and duration details are provided.

The outcome measures, be it primary or secondary outcome, should be identified and defined as part of the Methods section in order to allow readers to use the same outcomes for their own setting.\[[@ref7]\] It is not uncommon that the initial objective and protocol are amended throughout the course of the trial. In which case, this change should be reported.

The process of establishing an ethically and scientifically approved trial sample size needs to be noted and justified. Such information needs to provide evidence of the statistical power of the sample population under study. Furthermore, the randomization protocol of the sample population into the intervention and the control groups must be noted. Trials that follow a blinding protocol need to ensure the following: how such blinding was done, who knew about the blinding, was blinding initiated from the start of the trial, among other details. This is to ensure that any potential bias in the results is identified and accounted for.\[[@ref3]\]

A detailed description of all the statistical analyses of the data obtained from all stages of the trial needs to be reported.

Item 13 to 19: Results {#sec2-4}
----------------------

The CONSORT flowchart, as seen in [Figure 1](#F1){ref-type="fig"}, is provided to guide the author to the details required in the Results section. It is strongly recommended that the author utilizes the CONSORT flowchart to illustrate the trial outcomes. A detailed account of the intervention and the control groups are required including any loss of follow-up and any individual exclusion that occurred during the trial. If the trial ended prematurely, the reasons contributing to this need to be reported. It is suggestible to illustrate the baseline characteristics of the population under study followed by the primary and secondary outcomes of the study. Furthermore, any harms or unintended effects originating from the trial need to be reported.

Item 20 to 22: Discussion {#sec2-5}
-------------------------

The Discussion section should include supporting evidence to the trial\'s findings along with the pros and cons of the results obtained. Any external validation performed needs to be reported and discussed.

Item 23: Other information {#sec2-6}
--------------------------

The clinical trial should be registered at the very beginning in order to avoid any patency or infringement issues. Such details are required to be included in the manuscript reporting the clinical trial. The details of where a reader can access the full trial protocol needs to be included as well. Clinical trials are very expensive to conduct and funding will be required for it to be successful. All funding sources and the role of the funders in the trial\'s protocol are imperative to be stated in manuscripts.

Conclusion {#sec1-4}
==========

The CONSORT statement is a constantly updated guideline developed to aid RCTs authors in adequately reporting any trial. A 25-checklist and a flowchart comprise the CONSORT statement. Reporting and publishing trials in any journal require the authors to follow the CONSORT statement while writing their manuscript to ensure publication consideration.
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